Fig. 4From: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialRates of all hematologic adverse events, and of neutropenia, thrombocytopenia, and anemia over time in the QUAZAR AML-001 trialBack to article page